Literature DB >> 6228745

Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis.

S Berrih, E Morel, C Gaud, F Raimond, H Le Brigand, J F Bach.   

Abstract

The relationship between the titers of antibody against acetylcholine receptor (AChR) and T helper/suppressor balance (assessed by the OKT4/OKT8 ratio) were investigated in 74 patients with myasthenia gravis (MG). All patients with elevated AChR antibody titers (greater than 100 nM) had hyperplastic thymuses, while most patients with low or negative antibody titers (less than 1 nM) had involuted thymuses. All patients with thymoma had positive, though not very high, antibody titers. No correlation was found between anti-AChR antibody levels and OKT4/OKT8 ratios except for patients with thymoma. Thus, it appears that AChR antibody titers are more closely related to thymic pathology than to peripheral T cell imbalance. These results are consistent with the hypothesis giving a central role to thymic lymphocytes in the AChR antibody production, either as antibody producer B cells or helper T cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6228745     DOI: 10.1212/wnl.34.1.66

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.

Authors:  R Liblau; P Gajdos; F A Bustarret; R el Habib; J F Bach; E Morel
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

Review 3.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies.

Authors:  Sanjeev Rajakulendran; Stuart Viegas; Jennifer Spillane; Robin S Howard
Journal:  J Neurol       Date:  2012-09-07       Impact factor: 4.849

Review 5.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

6.  Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors:  Patrice Nancy; Sonia Berrih-Aknin
Journal:  Endocrinology       Date:  2005-01-20       Impact factor: 4.736

7.  Cellular aspects of myasthenia gravis.

Authors:  S Berrih-Aknin; S Cohen-Kaminsky; D Neumann; D Safar; B Eymard; C Gaud; P Levasseur; S Fuchs; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

Review 8.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

9.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

10.  An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis.

Authors:  A M Salmon; C Bruand; A Cardona; J P Changeux; S Berrih-Aknin
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.